Filing Details

Accession Number:
0001209191-23-002783
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-10 16:23:51
Reporting Period:
2023-01-06
Accepted Time:
2023-01-10 16:23:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819253 Biote Corp. BTMD Medicinal Chemicals & Botanical Products (2833) 851791125
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1931415 Sue Teresa Weber C/O Biote Corp.
1875 W. Walnut Hill Ln #100
Irving TX 75038
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-01-06 865,384 $0.00 950,424 No 4 C Direct
Class V Common Stock Disposition 2023-01-06 865,384 $0.00 2,967,092 No 4 J Direct
Class A Common Stock Disposition 2023-01-09 865,384 $3.00 85,040 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 J Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Retained Biote Units Disposition 2023-01-06 865,384 $0.00 865,384 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,967,092 No 4 C Direct
Footnotes
  1. Represents the exchange of Retained Biote Units ("Units") for shares of Class A Common Stock and the cancellation of an equivalent number of shares of Class V Common Stock in connection therewith.
  2. These shares of Class V Common Stock of the Issuer provide no economic rights in the Issuer to the holder thereof. However, each holder of Class V Common Stock will be entitled to vote with the holders of Class A Common Stock of the Issuer, with each share of Class V Common Stock entitling the holder to a number of votes equal to the number of Units held by such Class V Common Stock holder at the time of such vote.
  3. Received pursuant to the Business Combination Agreement between Haymaker Acquisition Corp. III, a Delaware corporation, Haymaker Sponsor III LLC, a Delaware limited liability company, BioTE Holdings, LLC, a Nevada limited liability company ("Biote"), BioTE Management, LLC, a Nevada limited liability company, Dr. Gary Donovitz, in his individual capacity and Teresa S. Weber, in her capacity as the members' representative ("the BCA").
  4. The Units represent non-voting limited liability company interests of Biote. Pursuant to the terms of the Second Amended and Restated Operating Agreement, beginning November 26, 2022, these Units and an equivalent number of shares of Class V Common Stock are exchangeable on a one-for-one basis for shares of Class A Common Stock, subject to certain conditions, or, in certain circumstances, at the election of the Issuer in its capacity as the sole manager of Biote, the cash equivalent of the market value of one share of Class A common stock. These exchange rights do not expire.